Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00946374 | Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma(HD-MCL2003) | unknown | Phase 2 | 20 | Heidelberg UniversityOTHER | 1 | Jul 27, 2009 | clinicaltrials |
| NCT00210327 | VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy | completed | Phase 2 | 33 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jul 22, 2009 |
| clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00927797 | Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)(PERLL) | unknown | Phase 2 | 185 | Heidelberg UniversityOTHER | 0 | Jun 25, 2009 | clinicaltrials |
| NCT00373646 | Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients | completed | Phase 2 | 8 | Medical University of ViennaOTHER | 1 | Jun 18, 2009 | clinicaltrials |
| NCT00781170 | Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma | completed | Phase 2 | 20 | Universitätsklinikum Hamburg-EppendorfOTHER | 0 | May 28, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00859001 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy(FM+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Mar 12, 2009 | clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00850512 | Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy(CHOP21+R-Z) | completed | Phase 2 | 55 | University of BolognaOTHER | 1 | Feb 25, 2009 | clinicaltrials |
| NCT00285389 | Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years | completed | Phase 2 | 39 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 12, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00804947 | Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | unknown | Phase 2 | 50 | Fundacion Para La Investigacion Hospital La FeOTHER | 1 | Dec 9, 2008 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00204659 | Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 30 | University Hospital TuebingenOTHER | 1 | Oct 20, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
| NCT00722930 | Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma(GOTEL-FL1LC) | unknown | Phase 2 | 38 | Grupo Oncológico para el Tratamiento y el Estudio de los LinfomasOTHER | 1 | Jul 28, 2008 | clinicaltrials |
| NCT00415987 | Hematopoietic Stem Cell Transplantation in Myeloma | unknown | Phase 2 / Phase 3 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00702247 | Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) | unknown | Phase 2 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00017680 | Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis | completed | Phase 2 | 25 | Herbert Irving Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2008 | clinicaltrials |
| NCT00455416 | Dietary Intervention in Follicular Lymphoma(KLYMF) | unknown | Phase 2 | 45 | Oslo University HospitalOTHER | 1 | May 21, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00001237 | Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas | completed | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001567 | A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00063713 | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 152 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00085696 | VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma | completed | Phase 2 | 66 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00304720 | Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor | unknown | Phase 2 | 40 | Colorado Blood Cancer InstituteOTHER | 1 | Feb 8, 2008 | clinicaltrials |
| NCT00090090 | Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 114 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jan 15, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00558220 | R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas(R-MCEB) | completed | Phase 2 | 106 | Czech Lymphoma Study GroupOTHER | 1 | Nov 14, 2007 | clinicaltrials |
| NCT00556127 | Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma(DLBCL) | completed | Phase 2 | 94 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Nov 9, 2007 | clinicaltrials |
| NCT00143884 | Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood | terminated | Phase 2 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 23, 2007 | clinicaltrials |
| NCT00455286 | a Phase II Study in Primary Central Nervous System Lymphoma | unknown | Phase 2 | 25 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 4, 2007 | clinicaltrials |
| NCT00327314 | Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma | unknown | Phase 2 | 100 | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Dec 28, 2006 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00048464 | T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | unknown | Phase 1 / Phase 2 | 35 | Xcyte TherapiesINDUSTRY | 1 | Nov 7, 2006 | clinicaltrials |
| NCT00393107 | Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab | completed | Phase 2 | 54 | Gruppo Italiano Studio LinfomiOTHER | 1 | Oct 26, 2006 | clinicaltrials |
| NCT00261612 | Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma | unknown | Phase 2 | 16 | Medical University of ViennaOTHER | 1 | Oct 18, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00382694 | Fludarabine Added to Induction Treatment in Untreated Multiple Myeloma Patients | unknown | Phase 2 | 80 | Nordic Myeloma Study GroupOTHER | 1 | Sep 29, 2006 | clinicaltrials |
| NCT00333008 | A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | unknown | Phase 2 | 27 | The Alvin and Lois Lapidus Cancer InstituteOTHER | 1 | Sep 26, 2006 | clinicaltrials |
| NCT00378755 | Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM | unknown | Phase 2 | 62 | Korean Multiple Myeloma Working PartyOTHER | 1 | Sep 22, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Jul 27, 2009source: clinicaltrials